期刊
MOLECULES
卷 27, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/molecules27072263
关键词
respiratory syncytial virus; antivirals; viral diseases; respiratory diseases; childhood infections
资金
- Russian Science Foundation (Moscow, Russia) [21-13-00026]
- Russian Science Foundation [21-13-00026] Funding Source: Russian Science Foundation
RSVI is a global acute medical and social problem, especially dangerous for infants under one year old and the elderly. Currently, only two drugs are available for clinical use against RSVI and they have limitations. Various research groups are searching for new drugs against RSV, with focus on small molecules, polymeric drugs, and plant extracts.
Respiratory syncytial virus infection (RSVI) is an acute medical and social problem in many countries globally. Infection is most dangerous for infants under one year old and the elderly. Despite its epidemiological relevance, only two drugs are registered for clinical use against RSVI: ribavirin (approved in a limited number of countries due to side effects) and palivizumab (Synagis), which is intended only for the prevention, but not the treatment, of infection. Currently, various research groups are searching for new drugs against RSV, with three main areas of research: small molecules, polymeric drugs (proteins and peptides), and plant extracts. This review is devoted to currently developed protein and peptide anti-RSV drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据